






KRISHZYME™ Prekallikrein Activator Assay Kit

REF: KBBA30EP

Ver2.0
(90 test)

RUO

KRISHZYME™ Prekallikrein Activator Assay kit is a chromogenic assay for measuring Prekallikrein Activator (PKA) in human blood products and biologicals according to European Pharmacopeia.

RUO	For Research Use Only	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions

*For Research & Industrial Purposes Only. **NOT** for use in diagnostic or therapeutic procedures. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.*

KRISHGEN BioSystems Unit Nos#318/319, Shah & Nahar, Off Dr. E Moses Road, Worli, Mumbai, Maharashtra 400018. India. |Tel: 022 4919 8700 | Email: info@krishgen.com

Introduction:

Plasma Prekallikrein (EC 3.4.21.34), is the glycosylated single chain zymogen precursor of the plasma serine protease kallikrein. Kallikrein activates plasminogen in fibrinolysis and cleaves kininogen in the bradykinin system of vasodilation.

Intended Use:

KRISHZYME™ Plasma Kallikrein Activator Assay Kit utilizes the ability of active plasma kallikrein to cleave a synthetic pNA-based peptide substrate to release pNA, which can be easily quantified using a microplate reader. The kit is easy-to-use and can detect PK activity of purified plasma kallikrein and plasma samples according to the procedure recommended by the European Pharmacopoeia.

Principle:

Plasma Prekallikrein is activated to plasma kallikrein by Prekallikrein activator (PKA -FXIIa). The kallikrein formed releases p-nitroaniline (pNA) from the kallikrein substrate. The rate at which the pNA is released is measured photometrically at 405 nm in a microtitre plate reader. The amount of pNA released is proportional to the amount of PKA present in the preparation up to a concentration of 32 IU/ml. The assay can be performed as rate method as recommended by the European Pharmacopoeia (EP), or by end point. The Human Prekallikrein in the kit is prepared according to the procedure recommended by the European Pharmacopoeia.

Materials Provided:

1. Human Prekallikrein - 2 vials x 2.5 ml
2. Kallikrein Substrate - 2 vials x 1 ml
3. PKA Standard 32 IU/ml - 1 vial x 1 ml
4. Buffer A Concentrate - 1 vial x 6 ml
5. Sample/Standard Diluent – 1 x 6ml
6. Quality Control – 1 x 0.5 ml
7. Assay Diluent - 1 vial
8. Microtitre Plates - 2 nos
9. Instruction Manual

Materials to be provided by the End-User:

1. Microplate Reader / Spectrophotometer able to measure absorbance at 405nm
2. Adjustable pipettes to measure volumes ranging from 10 ul to 2500 ul, duly calibrated
3. 1.5 ml Eppendorf tubes
4. Deionized (DI) water
5. Parallel line software for data analysis, if required
6. 37°C water bath or dry bath
7. 50% Glacial Acetic Acid
8. Timer/Stop watch
9. Absorbent paper

Storage and Stability Information:

Unreconstituted (lyophilized) reagents are stable until the expiration date indicated on the label when stored at 2° to 8° C.

1. Human PreKallikrein

Upon reconstitution, store at room temperature before use for up to 6 hours. For long term storage, the reagent can be stored for 6 months at -20°C.

2. Kallikrein Substrate

Stability before dilution for 8 hours at room temperature, 48 hours at 4°C, or at -20°C for 6 months. Upon reconstitution, store for 6 hours at room temperature or 24 hours at 4°C

3. PKA Standard

Upon reconstitution, store at 4°C before use for upto 8 hours, or freeze at -20°C for 6 months.

4. Assay Diluent

Upon reconstitution, store at room temperature for up to 8 hours or for longer term storage at -20°C for 6 months.

Health Hazard Warnings:

1. The source materials have been found to be non-reactive for Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus Type 1 and Type 2 (HIV-1, HIV-2) using FDA approved methods. However adequate care should be taken when handling these materials as a source for potentially infective agents.
2. The Buffer contains Sodium Azide as preservative. It may be harmful if ingested, inhaled or absorbed through the skin. Refer to product MSDS for details.
3. For Research Purpose and In-Vitro Laboratory Use Only.

Reagent Preparation:

Note: 1) Bring all reagents to room temperature.
2) All reagents should be diluted immediately prior to use.

1. Human Prekallikrein

Reconstitute in 2.5 ml sterile distilled water. Mix well before use.

2. Kallikrein Substrate

Reconstitute in 1 ml sterile distilled water and then dilute 1 ml with 9 ml Buffer B before use.

3. PKA Standard 32 IU/ml

Reconstitute in 1.0 ml of sample/standard diluent, leave for 5 minutes at room temperature and mix well. This gives a PKA concentration of 32 IU/ml.

4. Buffer A Concentrate

Tris-HCl buffer (100 mmol/l Tris) containing NaCl (24 mmol/l). Store at 4°C. The vial contains 6ml of concentrated buffer. Before use dilute the contents of the vial with sterile distilled water to give a final volume of 12ml in the vial. (Buffer A)

5. Buffer B

Dilute 1 ml of Buffer A with 9 ml sterile distilled water.

6. Assay Diluent

Dissolve vial contents in 6 ml sterile distilled water.

Specimen Dilution:

Dilute 100 µl of each plasma fraction with 100 µl of Assay Diluent.

Calibrator Concentration Preparation:

Dilute the PKA Standard with Assay Diluent to give PKA values as follows:-

Sr No.	PKA Concentration (IU/ml)	PKA Standard (µl)	Assay Diluent (µl)
S1	2.0	25	375
S2	4.0	50	350
S3	8.0	100	300
S4	16.0	100	100

Assay Protocol:

Particulars	Tubes
Preparation of Standards and Test Samples	
Pipette PKA prepared Standards into respective microtitre plate wells	25 µl
Pipette diluted test samples into respective microtitre plate wells	25 µl
Add Prekallikrein Solution into respective microtitre plate wells	50 µl
Preparation of Standards and Test Sample Blanks	
Pipette PKA prepared Standard into respective microtitre plate wells	25 µl
Pipette diluted test samples into respective microtitre plate wells	25 µl
Add Buffer A into respective tubes	50 µl
Transfer the microtitre plate immediately to a plate reader set at 37°C. Mix, and incubate for exactly 10 minutes	
Transfer solution from all tubes to respective microwells by pipette in duplicates	25 µl
Add prewarmed at 37°C, diluted PKA Substrate into microwells	100 µl
Transfer the microplate immediately to a microplate reader set at filter reading of 405nm and 37°C	
For Kinetic Assay	
Measure the absorbance change for a total of 5 minutes, starting at 3 minutes through to 8 minutes, depending on your instrumentation and protocols.	in microplate reader
Plot the Absorbance subtracted for respective blanks against PKA Concentrations (IU)	
For End-Point Assay	
Incubate the microplate for exactly 5 minutes at 37°C.	
Stop the reaction by addition of 50% Acetic Acid	25 µl
Mix and measure the absorbance at 405nm.	
Plot the Absorbance subtracted for respective blanks against PKA Concentrations (IU)	

Calculation of Results:



Calculate the Absorbance of each Standard and Test Sample by subtracting the optical densities obtained for the blanks of the Standards and Test Samples from the optical densities obtained for the Standards and Test Samples.

Plot these corrected (blanked) Absorbance of the Standards against PKA Standard Concentrations using a software or linear Graph Paper. Alternately you may also calculate the log Absorbances against the log PKA Standard Concentrations (Log/Log Standard Curve) using a software or log-log Graph Paper.

Calculate the PKA values of the Test Samples from the Standard Curve multiply the values obtained by 2.0 (being the dilution factor of the Test Samples).

Any Test Samples with PKA values greater than 32 IU/ml must be further diluted with Assay Diluent and re-tested until the absorbance value is obtained within the range of the standard curve. The value then obtained from the standard curve must be multiplied by the total dilution factor to give the actual PKA activity in the test sample.

Typical Standard Curves as given below:



Performance Characteristics:

Kit Standardization: The assay kit is standardized against the 2nd International Standard for PKA. It is recommended that the PKA high and low positive accuracy controls designed for use with the Prekallikrein Activator (PKA) Assay kit are run with each batch of tests.

Assay Range: 2 – 16 IU/ml

Precision: (n=20)
Intra-Assay CV < 7%
Inter-Assay CV < 9%

Recovery by Spiking:

The recovery from Human Albumin solutions spiked with known PKA concentrations (5 to 29IU/ml) yielded on average 98% (96-105%) of the theoretical expected value.

LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the product; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non-Krishgen made products or components. This warranty also does not apply to product to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective product in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the product. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Biosystems. 2024

THANK YOU FOR USING A KRISHGEN PRODUCT!